Ohio, USA-based contract development and manufacturing organization (CDMO) Andelyn Biosciences has partnered with Purespring Therapeutics in the area of nephrology.
Andelyn, an advanced therapy specialist, will help accelerate the manufacture of Purespring’s gene therapies for chronic renal diseases, bringing to bear its 185,000 square foot (17,200 square meter) GMP-compliant manufacturing facility.
Purespring is working on therapies that have the potential to stop or significantly slow down chronic kidney diseases that are currently poorly addressed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze